Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm is developing a non-radioactive and precision diagnostic molecular imaging technology. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The company uses bio-safe magnetic nanoparticles to detect cancer and other diseases. The firm operates through Research and Development segment. Its MagSense HER2 Imaging Agent (MSH2IA) is a first-in-class molecular imaging product candidate that is intended to detect tumors more accurately than relying solely on anatomical abnormalities seen in conventional imaging. With its tumor targeting, MSH2IA produces Magnetic resonance imaging (MRI) images that are differentiable between an abnormal lymph node and a normal node in HER2 positive breast cancer patients undergoing axillary imaging. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
